Evidence map›Paper›PMID 27485059›Full record

SynthesisHPB : the official journal of the International Hepato Pancreato Biliary Association2016

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Wilson Petrushnko, Justin S Gundara, Philip R De Reuver, Greg O'Grady, Jaswinder S Samra, Anubhav Mittal

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Overexpressed long noncoding RNAOncoTargets and therapy · 2019
    Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Wilson PetrushnkoUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia.
Justin S GundaraUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia.
Philip R De ReuverUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia.
Greg O'GradyDepartment of Surgery, University of Auckland, New Zealand.
Jaswinder S SamraUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia.
Anubhav MittalUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia. Electronic address: anubhav.mittal@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) continues to be associated with a poor prognosis. This systematic review aimed to summarize the literature regarding potential prognostic biomarkers to facilitate validation studies and clinical application.

methodsA systematic review was performed (2004-2014) according to PRISMA guidelines. Studies were ranked using REMARK criteria and the following outcomes were examined: overall/disease free survival, nodal involvement, tumour characteristics, metastasis, recurrence and resectability.

results256 biomarkers were identified in 158 studies. 171 biomarkers were assessed with respect to overall survival: urokinase-type plasminogen activator receptor, atypical protein kinase C and HSP27 ranked the highest. 33 biomarkers were assessed for disease free survival: CD24 and S100A4 were the highest ranking. 17 biomarkers were identified for lymph node involvement: Smad4/Dpc4 and FOXC1 ranked highest. 13 biomarkers were examined for tumour grade: mesothelin and EGFR were the highest ranking biomarkers. 10 biomarkers were identified for metastasis: p16 and sCD40L were the highest ranking. 4 biomarkers were assessed resectability: sCD40L, s100a2, Ca 19-9, CEA.

conclusionThis review has identified and ranked specific biomarkers that should be a primary focus of ongoing validation and clinical translational work in PDAC.

Indexed as

PancreatectomyBiomarkers, TumorCarcinoma, Pancreatic DuctalDisease-Free SurvivalDisease ProgressionHumansLymphatic MetastasisNeoplasm GradingNeoplasm Recurrence, LocalPancreatic NeoplasmsPredictive Value of TestsRisk FactorsTime FactorsTreatment OutcomeBiomarkers, Tumor

Identifiers

PMID27485059
PMCPMC4972371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.